PDX Pharmaceuticals

PDX Pharmaceuticals started in 2010 as a spinoff from the Biomedical Engineering Department at OHSU. The company has developed novel cancer therapeutics by combining nanotechnology and cancer systems biology in collaboration with the Knight Cancer Institute (KCI) of OHSU. PDX Pharma is conducting IND enabling studies of its first drug candidate (AIRISE™) and is raising $15M to initiate the clinical trial of AIRISE™ in 2022 and advance ARAC™ to clinics by 2023.

Company Details